Pharmacokinetics of sulfobutylether-b-cyclodextrin (SBECD) in subjects on hemodialysis

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 1207-1212

  Luke, David R ^a   Wood, Nolan D ^b   Tomaszewski, Konrad E ^b   Damle, Bharat ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Cyclodextrin; Hemodialysis; Pharmacokinetics; SBECD; Voriconazole

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; CREATININE; VORICONAZOLE; ANTIFUNGAL AGENT; BETA CYCLODEXTRIN DERIVATIVE; EXCIPIENT; PYRIMIDINE DERIVATIVE; SULFOBUTYLETHER BETA CYCLODEXTRIN; SULFOBUTYLETHER-BETA-CYCLODEXTRIN; TRIAZOLE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS MEMBRANE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ELIMINATION REACTION; GAIT DISORDER; GLOMERULUS FILTRATION RATE; HALF LIFE TIME; HALLUCINATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MEMBRANE TRANSPORT; MENTAL DISEASE; MORNING DOSAGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SLURRED SPEECH; THORAX PAIN; TREATMENT DURATION; VISUAL HALLUCINATION; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FOLLOW UP; METABOLISM; PROGNOSIS; RENAL REPLACEMENT THERAPY; TISSUE DISTRIBUTION;

ADULT; ANTIFUNGAL AGENTS; BETA-CYCLODEXTRINS; CASE-CONTROL STUDIES; EXCIPIENTS; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; PYRIMIDINES; RENAL DIALYSIS; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 84861117325     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr472     Document Type: Article

References (17)

1. Vfend Package Insert. http://www.pfizer.com/files/products/uspi-vfend.pdf (17 April 2011, date last accessed)
2. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol 1976; 83: 367-382
3. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008; 36: 30-42
4. Yong CS, Li DX, Prabagar B et al. The effect of ß-cyclodextrin complexation on the bioavailability and hepatotoxicity of clotrimazole. Pharmazie 2007; 62: 756-759
5. Potoski BA, Sima AP. Effect of intravenous voriconazole on serum creatinine in a population of patients with stable renal dysfunction. Presented at the 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008
6. Hafner V, Czock D, Burhenne J et al. Pharmacokinetics of sulfobutylether- ß-cyclodextrin (SBECD) and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010; 54: 2032-2041
7. Fuhrmann V, Schenk P, Jaeger W et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2007; 60: 1085-1090
8. Luke DR, Tomaszewski K, Damle B et al. Review of the basic and clinical pharmacology of sulfobutylether-ß-cyclodextrin (SBECD). J Pharm Sci 2010; 99: 3291-3301
9. Von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulfobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6: 1-6
10. Abel S, Allan R, Gandelman K et al. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects. Clin Drug Investig 2008; 28: 409-420
11. Gage R, Venn RF, Bayliss MAJ et al. Fluorescence determination of sulfobutylether-ß-cyclodextrin in human plasma by size exclusion chromatography with inclusion complex formation. J Pharm Biomed Anal 2000; 22: 773-780
12. Luke DR, Halstenson CE, Opsahl JA et al. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 1990; 48: 503-508
13. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64
14. Šefer S, Degoricija V. About drug dialyzability. Acta Clin Croat 2003; 42: 257-267
15. Johnson CA. Dialysis of Drugs. http://www.ckdinsights.com/downloads/ DialysisDrugs2009.pdf (17 April 2011, date last accessed)
16. Trotman RL, Williamson JC, Shoemaker DM et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-1166
17. Peng LW, Lien YH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Am J Kidney Dis 2005; 45: 162-166